Psilocybin for Depression Study Approved and Funded by German Government
Psilocybin Alpha, November 19, 2020
The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.
Canada Is Allowing People With Depression to Do Psychedelic Mushrooms
Vice World News, November 17, 2020
The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.
What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD
The Dales Report, November 11, 2020
The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.
Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’
CNBC, November 4, 2020
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.
Washington, DC, just decriminalized psychedelic plants. Here’s what happens next
Leafly, November 4, 2020
Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies.
Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020)
Ballotpedia, November 3, 2020
Oregon Measure 109, the Psilocybin Program Initiative was on the ballot in Oregon as an initiated state statute on November 3, 2020. It was approved.
Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms
Forbes, October 23, 2020
A Vancouver-based psychedelics company has become the first in Canada to complete a legal harvest of magic mushrooms since the last wave of psychedelic research ended there in the 1970s.
Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MAPS, October 14, 2020
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
Plos One, October 14, 2020
Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs. Treatment options are limited. A novel therapy using 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in six phase 2 trials. Its cost-effectiveness is unknown.
Are psychedelics the answer to depression and addiction?
Salon, April 22, 2018
A new generation of research into psilocybin could change how we treat numerous mental health conditions.